Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Monopar TherapeuticsMNPR · Entity 5152 | Chief Operating Officer | September 30, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Monopar Therapeutics
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,054 |
Ending reported balance
After 2026-09-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-30 · Exercise / conversion · Acquired 4,384 · Balance 59,998 F1: Represents shares acquired on vesting and settlement of restricted stock units. Row 2 · 2026-09-30 · Tax withholding · Disposed 1,944 · Balance 58,054 F2: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 35,115 |
Reported balance
After 2026-09-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-30 · Exercise / conversion · Disposed 4,384 · Balance 35,115 F1: Represents shares acquired on vesting and settlement of restricted stock units. F3: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4: On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5: On December 2, 2025, the reporting person was granted 13,919 restricted stock units, vesting 6/48ths (1,740) on June 30, 2026, and 3/48ths (870 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares acquired on vesting and settlement of restricted stock units.
F2: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.
F3: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
F4: On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
F5: On December 2, 2025, the reporting person was granted 13,919 restricted stock units, vesting 6/48ths (1,740) on June 30, 2026, and 3/48ths (870 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 2, 2026 22:15 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Unit · Derivative | 4,384 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-031927 · rdgdoc.xml · derivative · entry 3 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,115 Underlying: Common Stock · 4,384 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.exercise_date: On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.exercise_date: On December 2, 2025, the reporting person was granted 13,919 restricted stock units, vesting 6/48ths (1,740) on June 30, 2026, and 3/48ths (870 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.expiration_date: On December 2, 2025, the reporting person was granted 13,919 restricted stock units, vesting 6/48ths (1,740) on June 30, 2026, and 3/48ths (870 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| September 30, 2026 Filed Oct 2, 2026 22:15 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 1,944 | $79.67 | $154,878.48 |
DisclosureSEC source: 0001437749-26-031927 · rdgdoc.xml · nonDerivative · entry 2 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,054 F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| September 30, 2026 Filed Oct 2, 2026 22:15 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 4,384 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-26-031927 · rdgdoc.xml · nonDerivative · entry 1 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 23:37 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Unit · Derivative | 5,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-022628 · rdgdoc.xml · derivative · entry 3 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,499 Underlying: Common Stock · 5,254 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.exercise_date: On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.exercise_date: On December 2, 2025, the reporting person was granted 13,919 restricted stock units, vesting 6/48ths (1,740) on June 30, 2026, and 3/48ths (870 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.expiration_date: On December 2, 2025, the reporting person was granted 13,919 restricted stock units, vesting 6/48ths (1,740) on June 30, 2026, and 3/48ths (870 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 23:37 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 2,309 | $92.59 | $213,790.31 |
DisclosureSEC source: 0001437749-26-022628 · rdgdoc.xml · nonDerivative · entry 2 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,614 F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 23:37 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 5,254 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-26-022628 · rdgdoc.xml · nonDerivative · entry 1 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 19:03 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Unit · Derivative | 3,514 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-011078 · rdgdoc.xml · derivative · entry 3 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,753 Underlying: Common Stock · 3,514 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.exercise_date: On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 19:03 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 1,571 | $54.79 | $86,075.09 |
DisclosureSEC source: 0001437749-26-011078 · rdgdoc.xml · nonDerivative · entry 2 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,669 F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 19:03 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 3,514 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-26-011078 · rdgdoc.xml · nonDerivative · entry 1 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,240 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 20:45 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Unit · Derivative | 4,326 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-000305 · rdgdoc.xml · derivative · entry 3 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,267 Underlying: Common Stock · 4,326 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.exercise_date: On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.expiration_date: On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 20:45 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 1,889 | $65.30 | $123,351.70 |
DisclosureSEC source: 0001437749-26-000305 · rdgdoc.xml · nonDerivative · entry 2 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,726 F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 20:45 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 4,326 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-26-000305 · rdgdoc.xml · nonDerivative · entry 1 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| December 02, 2025 Filed Dec 8, 2025 21:50 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantRestricted Stock Units · Derivative | 13,919 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-037171 · rdgdoc.xml · derivative · entry 2 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,593 Underlying: Common Stock · 13,919 shares Expires not disclosed F2 · derivative.exercise_date: RSUs vest 6/48ths on June 30, 2026, and 3/48ths per quarter thereafter. F2 · derivative.expiration_date: RSUs vest 6/48ths on June 30, 2026, and 3/48ths per quarter thereafter. Read SEC document |
| December 02, 2025 Filed Dec 8, 2025 21:50 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 8,969 | $0.00 Strike: $75.94 | $0.00 |
DisclosureSEC source: 0001437749-25-037171 · rdgdoc.xml · derivative · entry 1 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,969 Underlying: Common Stock · 8,969 shares Expires 2035-12-02 F1 · derivative.exercise_date: Options vest 6/48ths on June 30, 2026, and 1/48th per month thereafter. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 19:04 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 4,327 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-030285 · rdgdoc.xml · derivative · entry 3 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,674 Underlying: Common Stock · 4,327 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.exercise_date: On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.expiration_date: On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 19:04 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 1,896 | $81.67 | $154,846.32 |
DisclosureSEC source: 0001437749-25-030285 · rdgdoc.xml · nonDerivative · entry 2 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,289 F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 19:04 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 4,327 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-030285 · rdgdoc.xml · nonDerivative · entry 1 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,185 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:24 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 6,863 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-021993 · rdgdoc.xml · derivative · entry 3 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,001 Underlying: Common Stock · 6,863 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.exercise_date: On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.expiration_date: On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:24 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 2,990 | $35.78 | $106,982.20 |
DisclosureSEC source: 0001437749-25-021993 · rdgdoc.xml · nonDerivative · entry 2 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,858 F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:24 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 6,863 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-021993 · rdgdoc.xml · nonDerivative · entry 1 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,848 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| March 31, 2025 Filed Apr 3, 2025 01:08 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 744 | $36.41 | $27,089.04 |
DisclosureSEC source: 0001437749-25-010810 · rdgdoc.xml · nonDerivative · entry 2 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,985 F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| March 31, 2025 Filed Apr 3, 2025 01:08 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 1,791 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-010810 · rdgdoc.xml · nonDerivative · entry 1 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,729 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| March 04, 2025 Filed Mar 8, 2025 02:09 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantRestricted Stock Units · Derivative | 40,581 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-006735 · rdgdoc.xml · derivative · entry 2 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,655 Underlying: Common Stock · 40,581 shares Expires not disclosed F2 · derivative.exercise_date: RSUs vest 6/48ths on June 30, 2025, and 3/48ths per quarter thereafter. F2 · derivative.expiration_date: RSUs vest 6/48ths on June 30, 2025, and 3/48ths per quarter thereafter. Read SEC document |
| March 04, 2025 Filed Mar 8, 2025 02:09 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 43,445 | $0.00 Strike: $31.70 | $0.00 |
DisclosureSEC source: 0001437749-25-006735 · rdgdoc.xml · derivative · entry 1 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,445 Underlying: Common Stock · 43,445 shares Expires 2035-03-04 F1 · derivative.exercise_date: Options Vests 6/48ths on June 30, 2025, and 1/48th per month thereafter. Read SEC document |
| December 31, 2024 Filed Jan 2, 2025 23:15 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 1,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-000097 · rdgdoc.xml · derivative · entry 3 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,074 Underlying: Common Stock · 1,790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| December 31, 2024 Filed Jan 2, 2025 23:15 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 721 | $22.00 | $15,862.00 |
DisclosureSEC source: 0001437749-25-000097 · rdgdoc.xml · nonDerivative · entry 2 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,938 F1 · shares: Represents shares acquired on vesting and settlement of restricted stock units. F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · balance_after: On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| December 31, 2024 Filed Jan 2, 2025 23:15 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 1,790 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-000097 · rdgdoc.xml · nonDerivative · entry 1 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 23:44 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 1,791 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-030535 · rdgdoc.xml · derivative · entry 3 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,864 Underlying: Common Stock · 1,791 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F1 · derivative.exercise_date: Effective on August 12, 2024, Monopar Therapeutics Inc effected a 5 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F4 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F1 · derivative.expiration_date: Effective on August 12, 2024, Monopar Therapeutics Inc effected a 5 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F4 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F1 · balance_after: Effective on August 12, 2024, Monopar Therapeutics Inc effected a 5 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 23:44 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 535 | $6.74 | $3,605.90 |
DisclosureSEC source: 0001437749-24-030535 · rdgdoc.xml · nonDerivative · entry 2 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,869 F2 · shares: Represents shares acquired on vesting and settlement of restricted stock units. F3 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. F2 · price: Represents shares acquired on vesting and settlement of restricted stock units. F1 · balance_after: Effective on August 12, 2024, Monopar Therapeutics Inc effected a 5 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F4 · balance_after: On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 23:44 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 1,791 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-030535 · rdgdoc.xml · nonDerivative · entry 1 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 22:12 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 8,952 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-022025 · rdgdoc.xml · derivative · entry 3 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,271 Underlying: Common Stock · 8,952 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,890 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,890 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 22:12 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 2,019 | $0.73 | $1,475.89 |
DisclosureSEC source: 0001437749-24-022025 · rdgdoc.xml · nonDerivative · entry 2 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,065 F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 22:12 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 8,952 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-022025 · rdgdoc.xml · nonDerivative · entry 1 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,084 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 21:16 UTC | Monopar Therapeutics MNPR · Entity 5152 | PurchaseCommon Stock | 20,508 | $0.74 | $15,253.85 |
DisclosureSEC source: 0001437749-24-021000 · rdgdoc.xml · nonDerivative · entry 2 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,132 F1 · kind: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.73691 to $0.75860, inclusive. The reporting person undertakes to provide to Monopar Therapeutics, any security holder of Monopar Therapeutics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in the preceding sentence. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 21:16 UTC | Monopar Therapeutics MNPR · Entity 5152 | PurchaseCommon Stock | 12,000 | $0.86 | $10,320.00 |
DisclosureSEC source: 0001437749-24-021000 · rdgdoc.xml · nonDerivative · entry 1 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,624 Read SEC document |
| June 17, 2024 Filed Jun 17, 2024 22:08 UTC | Monopar Therapeutics MNPR · Entity 5152 | PurchaseCommon Stock | 12,000 | $0.90 | $10,798.80 |
DisclosureSEC source: 0001437749-24-020547 · rdgdoc.xml · nonDerivative · entry 3 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,624 Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 22:08 UTC | Monopar Therapeutics MNPR · Entity 5152 | PurchaseCommon Stock | 12,000 | $0.93 | $11,175.60 |
DisclosureSEC source: 0001437749-24-020547 · rdgdoc.xml · nonDerivative · entry 2 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,624 F1 · kind: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9100 to $0.93994, inclusive. The reporting person undertakes to provide to Monopar Therapeutics, any security holder of Monopar Therapeutics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in the preceding sentence. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 22:08 UTC | Monopar Therapeutics MNPR · Entity 5152 | PurchaseCommon Stock | 12,000 | $0.91 | $10,920.00 |
DisclosureSEC source: 0001437749-24-020547 · rdgdoc.xml · nonDerivative · entry 1 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,624 Read SEC document |
| June 04, 2024 Filed Jun 5, 2024 22:12 UTC | Monopar Therapeutics MNPR · Entity 5152 | PurchaseCommon Stock | 12,000 | $0.78 | $9,360.00 |
DisclosureSEC source: 0001437749-24-019370 · rdgdoc.xml · nonDerivative · entry 2 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,624 Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 22:12 UTC | Monopar Therapeutics MNPR · Entity 5152 | PurchaseCommon Stock | 12,000 | $0.76 | $9,120.00 |
DisclosureSEC source: 0001437749-24-019370 · rdgdoc.xml · nonDerivative · entry 1 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,624 Read SEC document |
| May 31, 2024 Filed May 31, 2024 20:56 UTC | Monopar Therapeutics MNPR · Entity 5152 | PurchaseCommon Stock | 12,000 | $0.64 | $7,731.60 |
DisclosureSEC source: 0001437749-24-018931 · rdgdoc.xml · nonDerivative · entry 3 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,624 F3 · kind: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.61 to $0.6502, inclusive. The reporting person undertakes to provide to Monopar Therapeutics, any security holder of Monopar Therapeutics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in the preceding sentence. Read SEC document |
| May 30, 2024 Filed May 31, 2024 20:56 UTC | Monopar Therapeutics MNPR · Entity 5152 | PurchaseCommon Stock | 12,000 | $0.64 | $7,676.40 |
DisclosureSEC source: 0001437749-24-018931 · rdgdoc.xml · nonDerivative · entry 2 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,624 F2 · kind: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.629 to $0.64, inclusive. The reporting person undertakes to provide to Monopar Therapeutics, any security holder of Monopar Therapeutics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in the preceding sentence. Read SEC document |
| May 29, 2024 Filed May 31, 2024 20:56 UTC | Monopar Therapeutics MNPR · Entity 5152 | PurchaseCommon Stock | 12,000 | $0.64 | $7,642.80 |
DisclosureSEC source: 0001437749-24-018931 · rdgdoc.xml · nonDerivative · entry 1 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,624 F1 · kind: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.629 to $0.637, inclusive. The reporting person undertakes to provide to Monopar Therapeutics, any security holder of Monopar Therapeutics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in the preceding sentence. Read SEC document |
| May 22, 2024 Filed May 24, 2024 20:59 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001437749-24-018353 · rdgdoc.xml · derivative · entry 1 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-05-22 F1 · derivative.exercise_date: Options vest 6/48ths on November 21, 2024 and 1/48th per month thereafter. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 00:35 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 8,952 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-010723 · rdgdoc.xml · derivative · entry 3 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,223 Underlying: Common Stock · 8,952 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,890 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,890 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 00:35 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 3,098 | $0.68 | $2,109.74 |
DisclosureSEC source: 0001437749-24-010723 · rdgdoc.xml · nonDerivative · entry 2 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,624 F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 00:35 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 8,952 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-010723 · rdgdoc.xml · nonDerivative · entry 1 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,722 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| March 31, 2024 Filed Apr 3, 2025 01:08 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 1,791 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-010810 · rdgdoc.xml · derivative · entry 3 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,864 Underlying: Common Stock · 1,791 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F3 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F3 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| December 31, 2023 Filed Jan 4, 2024 00:39 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 8,952 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-000486 · rdgdoc.xml · derivative · entry 3 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,175 Underlying: Common Stock · 8,952 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F2 · derivative.exercise_date: On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,890 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F2 · derivative.expiration_date: On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 78,234 restricted stock units, vesting 6/48ths (9,779 shares) on June 30, 2023, and 3/48ths (4,890 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| December 31, 2023 Filed Jan 4, 2024 00:39 UTC | Monopar Therapeutics MNPR · Entity 5152 | Tax withholdingCommon Stock | 3,098 | $0.34 | $1,053.94 |
DisclosureSEC source: 0001437749-24-000486 · rdgdoc.xml · nonDerivative · entry 2 Cittadine Andrew · CIK 0001863624 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,770 F3 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.